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Activation of methotrexate -phenylalanine by monoclonal antibody-
carboxypeptidase A conjugate for the specific treatment of ovarian cancer
in vitro
M-J Perron and M Page
Department ofBiochemistry, Faculty ofMedicine, Universite Laval, Sainte-Foy, Quetbec GJK 7P4, Canada
Summary Monoclonal antibody 4E3 directed against a glycosylated surface protein on human ovarian
teratocarcinoma cells (CRL-1572 cell line) was conjugated to bovine carboxypeptidase A (CPA) using a 3400
Da polyethylene glycol chain bearing an N-hydroxysuccinimide group at both ends. The conjugate preparation
was purified by fast protein liquid chromatography on a Superose 12/30 HR column. The 4E3-CPA conjugate
was recovered in the third fraction by SDS-PAGE analysis. The specific binding of the 4E3-CPA conjugate to
CRL-1572 cells was confirmed by a FACS analysis and the enzymatic activity of the conjugate remained while
tested with hippuryl-L-phenylalanine. In vitro cytotoxic assays on CRL-1572 cells showed that the prodrug
methotrexate-phenylalanine (MTX-Phe) alone was non-toxic (ID50> 1000 ng ml-1) but was selectively
converted to MTX when the cells were pretreated with 50 ig ml-1 4E3 -CPA conjugate, which enhanced
considerably the pharmacological activity of the prodrug with an ID50 of 70 ng ml-l. The co-culture assays
with CRL-1572 and MRC-5 cells (human normal lung diploid fibroblast cell lines) demonstrated the specificity
of the 4E3-CPA conjugate for the CRL-1572 cells since no cytotoxicity was observed on the MRC-5 cells.
When both cell lines were mixed in ratios ranging from 1:10 000 to 1:5 (CRL-1572:MRC-5), the significant
increase in the ID25 was correlated wtih the proportion of tumoral cells present in the cell inoculum. These
results suggest that MTX-Phe combined with 4E3-CPA conjugate is a promising model for a more selective
and localised anti-cancer chemotherapy based on the ADEPT concept.
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Conventional chemotherapy regimens using methotrexate
(MTX) lack both specificity and selectivity and are highly
nephrotoxic. Many attempts have been made to enhance the
localisation of anti-tumoral activity at the tumour site by
coupling MTX to monoclonal antibodies as specific carriers
to tumour antigens (Ghose et al., 1983; Kanellos et al., 1985).
Unfortunately, this approach has encountered many pro-
blems, such as a loss of pharmacological and/or immunolo-
gical activity of the conjugates, a partial recognition of the
targets by the conjugates due to the heterogeneity of the
tumour antigens and a poor penetration of the conjugates
into the tumour masses (Burstein and Knapp, 1977; Kralovec
et al., 1989a, b). Therefore, an MTX targeting model has not
yet been successful in cancer therapy.
In 1987 Bagshawe et al. introduced a new concept called
ADEPT (antibody-directed enzyme prodrug therapy). This
two-phase system first involves the delivery of an enzyme
coupled to a monoclonal antibody at the tumour site; second,
a non-toxic prodrug is activated by the targeted enzyme and
the drug released in the tumour vicinity is taken up by the
cells (Bagshawe, 1987, 1989; Bagshawe et al., 1988). This
approach allows the generation of large amounts of drug at
the tumour site by the action of the targeted enzymes. Thus,
heterogeneity in antigen expression or drug doses is no longer
a limiting factor since the prodrug is ideally an inert
compound. Kuefner et al. (1989) then reported that a
MTX-a-peptide made up of an amino acid linked to the a-
carboxyl group of MTX via an amide bond can act as a
prodrug, thereafter regaining its toxicity by a CPA-mediated
release of free MTX in the medium (Esswein et al., 1991;
Hanseler et al., 1992).
For many years, studies in this laboratory focused on the
optimisation of a drug-targeting model using MTX. With the
advent of the ADEPT concept and the many interesting
features related to this new strategy, efforts were made to find
the most suitable MTX prodrug for CPA. As we have
already reported (Perron and Page, 1994a), an extensive
synthesis and screening of 11 MTX-a-peptides selected on the
basis of their polarity and structure was carried out. Since the
prodrug MTX-Phe showed a cytotoxicity similar to the
commercially available MTX once hydrolysed by free CPA
(Perron and Page, 1994b), these experiments led us to
conclude that MTX-Phe was a potential substrate for the
ADEPT system.
In order to apply these new findings to a more selective
targeting model, bovine carboxypeptidase A was conjugated
to the monoclonal antibody 4E3 directed against a high
molecular weight glycosylated surface protein on human
ovarian teratocarcinoma cells (CRL-1572). This monoclonal
antibody was characterised in this laboratory (Lemieux and
Page, 1994). A novel coupling method using an N-
hydroxysuccinimidyl active ester of polyethylene glycol
succinate (SS2-PEG) as the cross-linking agent was chosen
for its simplicity and short reaction times. Following the
purification of the conjugate preparation by gel filtration,
FACS analysis confirmed the specific binding of 4E3-CPA
conjugate to CRL-1572 cells. Also, 4E3-CPA conjugate
retained its enzymatic activity when tested with hippuryl-L-
phenylalanine.
As described in this report, we evaluated the potential of
this new prodrug-enzyme combination for an application as
a complete ADEPT system in vitro. CRL-1572 cells were
pretreated with 4E3-CPA conjugate followed by an exposure
to prodrug MTX-Phe. A co-culture of CRL-1572 and MRC-
5 cells (human normal lung diploid fibroblast cell line), which
do not express the antigen targeted by the 4E3 -CPA
conjugate, was also tested as a tumour mass model.
Materials and methods
4E3 purification
Monoclonal antibody 4E3 was purified from mouse ascitic
fluid by affinity chromatography on a Sepharose-anti-mouse
IgG column equilibrated with phosphate-buffered saline
(PBS). Glycine-HCl 0.15 M pH 2.5 was used as the elution
buffer. Finally, fractions containing the purified 4E3 were
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dialysed overnight at 4°C against PBS, aliquoted and stored
at -20°C.
Synthesis of the 4E3-CPA conjugate
CPA and monoclonal 4E3 were conjugated using an amide
linkage via a 3400 Da PEG chain. Briefly, 12.5 nmol of the
purified 4E3 monoclonal antibody was mixed with 25 nmol
of bovine pancreatic CPA type II-DFP (EC 3.4.17.1)
purchased from Sigma Chemicals (St Louis, MO, USA).
An aliquot of 37.5 nmol of (SS2) PEG 3400 (Shearwater
Polymers, AL, USA) was added dropwise and the mixture
was gently stirred for 75 min at room temperature. The
reaction was stopped by the addition of 10 pl of
ethanolamine 0.01 M. The mixture containing 4E3, CPA
and the conjugate was passed through a Superose 12/30 HR
column (Pharmacia, Baie d'Urfee, QC, Canada) to remove
the free reagents.
SDS-PAGE analysis
Fractions were then analysed by SDS-PAGE. Electrophoresis
was performed on a PhasSystem (Pharmacia) using precast
4-15% gradient gels under non-reducing conditions. One
microlitre of each of the samples was applied to a 3%
stacking gel. Proteins were silver stained.
Cytometry analysis
A cytometry analysis was carried out in order to evaluate the
specific binding of the 4E3-CPA conjugate-containing
fractions to CRL-1572 cells. Cell suspensions of CRL-1572
in PBS-20% bovine serum albumin (BSA)-0.02% sodium
azide were incubated with each of the five fractions, 4E3 and
purified IgG from mouse normal serum as controls at a
concentration of 20 Mug ml-' for 30 min at 4°C. Cells were
washed twice with PBS-0.02% sodium azide. Cell pellets
were then resuspended with 50 Ml of an anti-IgG-FITC
solution. Following a 30 min incubation period at 4°C, cells
were washed as described above, resuspended in FACS Flow
and analysed on a FACScan (Becton-Dickinson, Mississauga,
Ontario, Canada).
Enzymatic and protein G affinity combined assay
The presence of CPA in the fractions can be proven by an
enzymatic assay and the presence of 4E3 by cytometry or
ELISA. Thus, in order to determine whether these two
components are linked together or not, we developed a test
that combines an enzymatic assay specific to CPA with an
affinity assay using protein G, which has the capacity to bind
selectively to IgG molecules. First, an enzymatic assay was
performed on each fraction and also on CPA as a control, as
we have already reported (Perron and Page, 1994b). Briefly,
1.0 mM hippuryl-L-phenylalanine in 2.95 ml of 0.1 M Tris-
HCl buffer pH 7.3-0.2 mM zinc sulphate was incubated at
37°C. The enzymatic reaction was initiated by adding 20 Mg
of CPA contained in 50 ul, giving a final reaction volume of
3.0 ml. The increase in absorbancy was monitored with a
Philips UV/Vis scanning spectrophotometer (Model PU 8720)
at 254 nm for 15 min. Fractions were then passed through
MAC Discs-protein G before the re-evaluation of their
enzymatic activity. MAC Discs-protein G are ready-to-use
purification devices purchased from Amicon (Oakville,
Ontario, Canada). Recombinant protein G is linked via a
very stable bond to chemically reactive affinity membranes
that are inserted into a holder. Multiple passes can be
accomplished by attaching a syringe to each end of the holder
and gently passing the sample back and forth through the
unit several times. Since CPA has no affinity for protein G,
an important decrease or a total inhibition of the enzymatic
activity after the sample passed through the discs is observed
when CPA is linked to 4E3, which is retained on the
membranes. A 0.6 dilution factor calculated for the MAC
Discs-protein G unit was used to readjust the concentration
of the samples before the affinity assay. The protein G
membranes were prewashed with the Tris-HCl buffer used for
the enzymatic assay. Samples containing 50 ,ug of each of the
fractions and CPA as a control were diluted in the prewash
buffer in order to obtain a final volume of 3.0 ml. Samples
were then passed 40 times through the protein G unit. The
enzymatic activity was then measured in the eluent as
previously described.
Cell lines
Cells were obtained frozen from the ATCC (Bethesda, MD,
USA). They were passaged once a week at 37°C/5% carbon
dioxide in RPMI-1640 culture medium (Flow Laboratories,
VA, USA) supplemented with 10% fetal bovine serum (FBS)
(Gibco Laboratories, NY, USA). CRL-1572 are ovarian
teratocarcinoma cells and MRC-5 are normal lung diploid
fibroblasts. Both lines are human anchorage-dependent cells.
Cytotoxic assays on CRL-1572 cells
Approximately 2000 cells were seeded into 100 jil of RPMI-
1640 culture medium- 10% FBS in 96-flat-bottom-well
microtitration plates. Cells were allowed to attach for 48 h
at 37°C/5% carbon dioxide. Aliquots of 80 jul/well of the
culture medium were removed from the plates and cells were
then pretreated with 30 ,ul of each 4E3-CPA-containing
fraction fixed at a concentration of 50 Mg ml-' with the
culture medium. Plates were incubated for 2 h at 4°C and
were subsequently washed four times with RPMI-1640.
MTX-Phe was then diluted in the culture medium
supplemented with 0.003 mM zinc sulphate in order to
achieve various prodrug concentrations ranging from
0 ng ml-' to 1000 ng ml-1. An aliquot of 200 iil of each
dilution was added to the cells. As controls, cells were also
tested with MTX-Phe and MTX without the 4E3-CPA
pretreatment. Cell growth was evaluated by the method
described by Page et al. (1994) as follows. After a 4 day
growth period, 10 Ml of AlamarBlue solution (Alamar
BioSciences, CA, USA) was added to each well and plates
were incubated for 3 h at 37°C. Fluorescence was read with
the Millipore CytoFluor 2000 plate reader (Mississauga,
Ontario, Canada) with an excitation at 530 nm and an
emission at 590 nm.
Co-culture assays
The procedure described above regarding CRL-1572 cyto-
toxic assays was applied for the co-culture assays except for
the cell inoculum. We deliberately contaminated MRC-5 cells
with various amounts of CRL-1572 cells in order to simulate
a tumour-like cell population. The platings were prepared as
follows. Approximately 10 000 MRC-5 cells were seeded into
50 ,l of RPMI-1640- 10% FBS in 96-well microtitration
plates, followed immediately by the addition of CRL-1572 in
various amounts ranging from 1 to 2000 cells/well also in
50 Ml of culture medium, giving a final volume of 100 ll.
Cells in the co-culture platings were allowed to attach for
48 h at 37°C/5% carbon dioxide and were handled as
described above for the remaining steps of the cytotoxic
assay. MTX-treated cells were used as a control.
Results
4E3- CPA conjugate
As described in Materials and methods, a novel procedure
using (SS2)PEG 3400 was carried out to conjugate CPA to
monoclonal 4E3 in replacement of the traditional cross-
linking agents. The PEG active ester derivative reacts with
amino groups on proteins under mild conditions within short
periods of time. A molar ratio of 1 4E3: 2 CPA: 3 PEG was
found optimal for the preparation of the reaction mixture in
order to favour the formation of mono-(4E3:CPA), di-
(4E3:2CPA) and tri-substituted (4E3:3CPA) conjugates.When the conjugate preparation was separated on a
Superose 12/30 HR column, the resulting elution profile
showed three distinct peaks (Figure 1). The first peak, which
corresponds to the void volume of the column, contained
compounds having a molecular weight of 300 kDa and more
(Fl 16.5-18.5 ml). A mixture of unreacted antibody
(160 kDa) and material between 160 kDa and 300 kDa was
recovered in the second peak (F2 18.5-20.5 ml; F3 20.5-
22.5 ml). Finally, unreacted enzyme (35 kDa) and other low
molecular weight components were eluted in the third peak
(F4 22.5-24.5 ml; F5 24.5-26.5 ml). The calculation of an
approximate yield for the conjugation reaction relied on the
enzymatic activity of the fractions of interest (Fl, F2 and F3)
instead of their protein content since unreacted antibody was
present in fraction F3. The overall yield for the conjugation
of 4E3 with CPA using PEG was evaluated at 18% and at
approximately 6% for fraction F3 alone. These results do not
take into account the possible loss of enzymatic activity
during the conjugation process and/or the likely presence of
CPA polymers in these fractions.
To obtain further information about the composition of
the three major peaks, the five corresponding fractions were
analysed by SDS-PAGE (Figure 2). Fl (lane 4) contained
high molecular weight material that did not migrate into the
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gel. F2 (lane 5) also exhibited traces of this high molecular
weight material, small amounts of two well-resolved
compounds at approximately 200-230 kDa and a substan-
tial amount of material which was well defined and slightly
heavier than unreacted 4E3 (control in lane 2). This last
component was also present in large amounts in F3 (lane 6)
along with unreacted 4E3 and a few compounds of lower
molecular weight. F4 and F5 (lanes 7 and 8 respectively)
revealed the presence of unreacted CPA as the major
constituent when compared with the CPA control in lane 3.
Following these findings, a FACS analysis was carried out
on the five fractions with CRL-1572 cells to evaluate the
specific binding of the conjugated material contained in these
three fractions. As demonstrated in Figure 3, F3 showed a
significant reactivity towards CRL-1572 cells similar to the
reactivity exhibited by the monoclonal 4E3 positive control.
The fluorescence intensity measured for F3 was about ten
times greater than the negative control, which is purified IgG
from mouse normal serum. However, the presence of
unreacted 4E3 in F3 may interfere with the capacity of F3
to bind to the cells, consequently the F3 reactivity should be
interpreted with caution. Fl and F2 were not as reactive as
F3, their respective fluorescence intensity was similar to the
control (data not shown). This indicates that high molecular
0)
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Figure 1 Elution profile following a purification on a Superose
12/30 HR column by FPLC. A 2ml loop was required to inject
the total volume (1.7ml) of the conjugate preparation containing
a total of 2 mg proteins. PBS was used as the elution buffer at a
flow rate of0.5mlmin-1. The elution was monitored at 280 nm at
0.5 AUFS.
F3
,4E3 MAb
4
Fluorescence intensity
Figure 3 Fluorescence labelling of CRL-1572 cells with FITC-
conjugated anti-IgG as the second antibody. Cells were initially
exposed to non-specific mouse IgG purified from normal serum
(control), F3 and 4E3 specific monoclonal antibody. (FACS
profiles for Fl, F2, F4 and F5 are not shown.)
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Figure 2 SDS-PAGE analysis of the conjugate fractions from the gel filtration on Superose 12. Aliquots of 200ng in 1 ,l of0.01 M
Tris-HCl pH 8.0-1 mm EDTA-2.5% SDS buffer of MW standards (lane 1), 4E3 control (lane 2), CPA control (lane 3), Fl (lane
4), F2 (lane 5), F3 (lane 6), F4 (lane 7) and F5 (lane 8) were applied on a 4-15% gradient gel. Electrophoresis proceeded for 45min
at 250V/lOmA/3W under non-reducing conditions.
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weight material found in F2 and especially in Fl lost its
immunological activity following an extensive conjugation
leading to the formation of protein aggregates and
polysubstituted 4E3-CPA conjugates. As expected, F4 and
F5 did not show any reactivity due to their enzymatic content
(data not shown).
All fractions were also tested for enzymatic activity and
their specific activity was calculated [Figure 4 (0)]. As
expected, F4 (44.3 units mg-') and F5 (44.1 units mg-')
showed the same profile as the CPA control (49.7 units mg-')
since F4 and F5 are mainly made up of unreacted CPA. Fl,
F2 and F3 hydrolysed hippuryl-L-phenylalanine to hippuric
acid at similar rates, Fl having the highest sp. act. (4.2
units mg-') followed by F3 (2.8 units mg-1) and F2 (1.2
unit mg-1). Since these are bulk fractions from which the
compound of interest, for instance 4E3-CPA conjugate, was
not purified, the sp. act. measured on the total protein
content was underestimated. When results obtained from
SDS-PAGE, FACS and enzymatic assays were compared, F3
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happened to be the most interesting fraction, since both
immunological and enzymatic activity were present. The
possibility that F3 could contain CPA polymers still
enzymatically active mixed with free antibody had to be
considered since Fl and F2 contained high molecular weight
material, indicating that polymerisation had obviously taken
place.
The presence of 4E3-CPA conjugate in F3 was tested as
follows: following the protein G assay, in which the F3
immunological component was bound to the affinity
membranes, an enzymatic assay was performed on the
supernatant to seek enzymatic activity [Figure 4 (0)]. By
comparison with the enzymatic activity in the fractions before
the protein G affinity assay [Figure 4 (0)], the presence of
unbound and 4E3-bound CPA in the fractions could be
established. F3 showed a residual peptidase activity following
the binding assay to protein G. This observation confirmed
the presence of CPA tri- or tetramers (c. 105 kDa and
104 kDa respectively) in F3 with respect to the bands
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Figure 4 Enzymatic activity of CPA and the five fractions on hippuryl-L-phenylalanine before (0) and after (0) the affinity
binding assay on protein G membranes.
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displayed on the SDS gel. We found that 4E3-CPA
conjugate had a sp. act. of 1.5 unit mg-' total protein. The
CPA activity in fractions Fl and F2 was completely retained
by the protein G absorbent while we found no difference in
activity in fractions F4 and F5.
Cytotoxic assays on CRL-1572 cells
In order to evaluate the potency of the 4E3-CPA conjugate
to selectively activate the non-toxic prodrug MTX-Phe to
MTX, CRL-1572 cells were exposed to fraction Fl, F2 or F3.
Cells were washed thoroughly to eliminate unbound material
such as unreacted CPA polymers, and then treated with
various concentrations of MTX-Phe. As controls, cells were
also treated with MTX-Phe and MTX without the Fl, F2 or
F3 pretreatment. Figure 5 shows that, when the cells were not
treated with either one of the fractions, MTX-Phe was not
cytotoxic (ID50> 1000 ng ml-'). The cytotoxicity of MTX-
Phe was slightly improved when the cells were initially
exposed to Fl or F2, showing an IDs0 of 250 ng ml-l and
500 ng ml-' respectively. This is in accordance with the
composition of these two fractions, which were characterised
by FACS analysis and enzymatic assays. Fl was more active
enzymatically than F2, but both fractions were not very
reactive towards CRL-1572 cells, suggesting that the majority
of Fl and F2 constituents had lost their immunological
activity and consequently their specific binding capacity to
those cells. However, when cells were pretreated with F3
before exposure to MTX-Phe, a marked reduction in growth
approaching the one of MTX (ID50 15 ng ml-') could be
observed. The IDs0 of MTX-Phe in these circumstances was
considerably enhanced to 70 ng ml-' when compared with
the initial ID50 of > 1000 ng ml-' for MTX-Phe alone. Fl,
F2 or F3 treatment alone was not toxic (data not shown).
Co-culture assays with CRL-1572 and MRC-5 cells
A co-culture of CRL-1572 and MRC-5cells (human normal
lung diploid fibroblast cell line), which do not express the
antigen targeted by the 4E3-CPA conjugate, was used as an
in vitro model of a heterogeneous tumour cell population and
to test the selectivity of the 4E3-CPA conjugate. MRC-5
cells were mixed in various proportions with CRL-1572 cells
ranging from 1 to 2000 CRL-1572 cells per 10 000 MRC-5
cells. As described above for the cytotoxic assays, the
different ratios of co-cultured cells were exposed to the
conjugate, washed thoroughly and then treated with various
concentrations of MTX-Phe. The same cell ratios were also
treated with free MTX. As shown in Figure 6, the
cytotoxicity of MTX-Phe on the CRL-1572/MRC-5 co-
culture, which was initially exposed to the conjugate,
decreased as the proportion of CRL-1572 cells in the
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inoculum was reduced. The comparison between the
ID50values of the positive control curve [2000 CRL-1572
cells (@, solid line)] and the 2000 CRL-1572/10000 MRC-5
cells curve (0, solid line), which are 70 ng ml-' and
80 ng ml-' respectively, shows that cells such as MRC-5,
which were not bearing the tumour antigen at their surface,
could be killed likewise iftargeted cells CRL-1572 were in the
immediate environment. The negative control curve [10000
MRC-5 cells (0, dashed line)] demonstrated clearly that in
the absence of CRL-1572 cells, MTX-Phe had no effect on
MRC-5, cells indicating that the conjugate bound specifically
to CRL-1572 cells and further activated the prodrug MTX-
Phe. To quantify the cytotoxicity for all curves (except for the
positive control), ID25 was used as the point of comparison
instead of ID50 since the majority of the dose-response
curves shown in Figure 6 were well below the 50% growth
inhibition threshold. The ID25 measured for each curve was
plotted in relation to the CRL-1572 cell number present in
the co-culture inoculum (Figure 7). Within the various cell
ratios (0 and 2000 CRL-1572/10 000 MRC-5 cells), the
observed ID25 was proportional to the CRL-1572/MRC-5
ratio. Treatment with MTX killed both CRL-1572 and
MRC-5 cell lines.
Discussion
The potential of a new prodrug-enzyme combination, in this
case MTX-Phe and carboxypeptidase A, was evaluated for an
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Figure 6 Dose-response curves showing the cytotoxic activity of
MTX-Phe following a pretreatment with F3 on a co-culture of
CRL-1572 and MRC-5 cells mixed in various ratios: 1:10000 (0,
dashed line), 1:200 (A), 1:100 (A), 1.20 (El), 1:10 (A) and 1:5
(0, solid line). MRC-5 cells (0, dashed line) and CRL-1572 cells
(0, solid line) were used as controls.
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Figure 5 Dose-response curves showing the cytotoxic activity of
MTX-Phe on CRL-1572 following a pretreatment with Fl (Ol),
F2 (U) and F3 (0). MTX (0) and MTX-Phe (A) were used as
controls.
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Figure 7 Correlation between the toxicity of MTX-Phe mediated
by F3 (4E3-CPA conjugate), expressed as ID25, and the amount
of CRL-1572 cells present in the co-culture inoculum.
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application as a complete ADEPT system in vitro. As we
have already reported (Perron and Page, 1994b), MTX-Phe
appeared the most appropriate substrate for CPA since the
presence of 1 milliunit of free enzyme in the culture medium
was sufficient to hydrolyse MTX-Phe to MTX, thus restoring
the toxicity of the parent drug. These conclusions were later
validated by a parallel study conducted by Vitols et al.
(1995).
To apply these findings to a more selective targeting
model, CPA was conjugated to monoclonal 4E3 directed
against human ovarian teratocarcinoma cells. For this
purpose, a novel coupling method using a N-hydroxysucci-
nimidyl active ester of polyethylene glycol succinate
[(SS2)PEG 3400] was developed, since the use of traditional
cross-linking agents for the derivatisation of CPA, such as,
succinimidyl -I -(maleimidomethyl)cyclohexane- 1-carboxylate
(SMCC) leads to unreproducible substitutions and unsatis-
factory yields when conjugated with N-succinimidyl-S-
acetylthioacetate (SATA)-derivatised 4E3. We improved the
conjugation conditions with the use of (SS2)PEG 3400, which
is considered as the reagent of choice for the attachment of
PEG to proteins and peptides (Abuchowski et al., 1984), and
the cross-linking of proteins yielding extensively modified yet
active and stable conjugates in which steric hindrance is
minimal with the use of' a long polyethylene spacer. The
conjugation of CPA to 4E3 with (SS2)PEG 3400 in the
conditions described was highly reproducible. On the other
hand, the evaluation of the substitution ratio of the active
material was puzzling due to the nature of the cross-linking
agent used and also by the fact that both reactants (4E3 and
CPA) were pooled together for the conjugation procedure.
Since hydroxysuccinimide esters react with lysines, the total
amount of free NH2 groups present on the proteins before
and after the conjugation procedure could have been
determined by the ninhydrin technique. However, this
technique is not sensitive enough on low substituted
material. Yet as shown by the SDS gel, the 4E3-CPA
conjugate found in fraction F3 was undoubtedly monosub-
stituted considering that the bands of interest in this fraction
ranged from 160 kDa to 190 kDa.
The purification of 4E3-CPA conjugate was carried out
in a single step. The conjugate was recovered in the third
fraction (F3) following a gel filtration on a Superose 12/30
HR column. The experiments were performed with the F3
fraction, which may contain traces of impurities. The absence
of free CPA in this fraction shows that the cytotoxicity
reported above was related to the activity of bound 4E3-
CPA conjugate on MTX-Phe prodrug. It was shown that
when CRL-1572 were pretreated with the conjugate before an
exposure to MTX-Phe, an ID50 of 70 ng ml-' could be
measured, approaching that of MTX (Figure 5). It was
estimated that a maximum of 1.3 CPA milliunit of conjugate
was delivered to each well. However, we have shown that the
ID50 of MTX-Phe reached a plateau when the amount of free
CPA in the culture medium exceeded 0.2 milliunits. This
observation was also confirmed by Vitols et al. (1995).
The selectivity of the 4E3-CPA/MTX-Phe combination
was emphasised by a co-culture assay in which CRL-1572
cells were plated in various ratios together with MRC-5 cells,
a human fibroblast cell line which is not targeted by 4E3. We
decided to seed both cell lines together in order to simulate a
tumour-like model in vitro instead of using co-culture inserts
that eliminate contact between cells, which is less representa-
tive of the cell-cell interactions. Wilson (1984) reported that
human ovarian tumour biopsies were frequently contami-
nated by stromal cells of fibroblastic or mesothelial origin
with no change in the chemosensitivity of the culture. Figure
6 shows that 4E3-CPA/MTX-Phe had no toxic effect on
MRC-5 cells alone. In addition, the cytotoxicity measured on
the CRL-1572 control curve was similar to that of the 1:5
(CRL-1572:MRC-5) curve with ID50 of 70 ng ml-1 and
80 ng ml-' respectively. This suggests that only 20%
antigen-positive cells was sufficient to achieve maximum
cytotoxicity. Nevertheless, as few as 0.5% antigen-positive
cells was sufficient to observe an increase in the cytotoxicity
of MTX-Phe (Figure 7). Since ID25 was well correlated with
the proportion of CRL-1572 in the inoculum, 4E3-CPA was
undoubtedly specific to CRL-1572 cells, thus conferring
selectivity to the prodrug MTX-Phe by the mediation of
4E3-CPA conjugate. These results meet one of the ADEPT
concept premises, which states that heterogeneity (or absence)
in antigen expression is no longer a limiting factor, a few cells
need to be targeted by the conjugate to produce an
amplification system allowing large amounts of drug to be
liberated in the tumour vicinity and taken up by the cells
regardless of their antigen expression.
Although the effectiveness of this new prodrug-enzyme
combination was shown above, the 4E3-CPA conjugate will
require further characterisation and improvements in order to
limit the antigenicity induced by the use of the whole IgG
molecule. We are presently preparing a conjugate with the Fv
fragment of 4E3 for testing in a xenograft model.
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